Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in the Treatment of Moderate to Severe Major Depressive Disorder (MDD): a Randomized, Double-blind Phase III Study of 10 Weeks

NCT01312922 is registered in ClinicalTrials.gov with PharmaNeuroBoost N.V. as lead sponsor.

NCT NCT01312922
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01312922 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in the Treatment of Moderate to Severe Major Depressive Disorder (MDD): a Randomized, Double-blind Phase III Study of 10 Weeks
Lead sponsor
PharmaNeuroBoost N.V.
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2011
Completion date
December 31, 2012
Enrollment
555 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

major depressive disorder